Delivery Order HHSF223201310033I-HHSF22301002T
Award Date
8/17/16
Potential Completion Date
5/1/21
Potential Value
$1.4M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Lovelace Biomedical Research Institute
PSC Category
R499 - Support- Professional: Other
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Albuquerque, NM 87108, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit research organization, to develop a standard guideline protocol for rodent tobacco smoke inhalation studies. The contract has a ceiling value of $1,373,599.00 and is a firm fixed-price task order issued under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The...
This is a firm fixed-price delivery order issued by the Department of Health and Human Services Food and Drug Administration under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract. The $1,408,956.00 task order was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to perform detection and characterization of DNA adducts generated by tobacco flavorants in aerosol...
This is a $897,471 firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. LBERI, a non-profit contract research organization, will provide preclinical research services to support the...
This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to conduct in vitro evaluation of the toxic profiles of tobacco additives in a systematic tiered approach. The contract has a ceiling value of $1,552,162.00 and an ultimate completion date of July 14, 2018. It was issued under the FDA's "In Vivo Toxicology of Tobacco...
This is a delivery order contract awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit organization, for a project titled "CYTOTOXICITY OF COMMON SOLVENTS USED IN LIQUID NICOTINE FORMULATIONS". The contract has a potential value of $1,149,919.00 and a completion date of April 15, 2021. This delivery order is part of a larger indefinite delivery/indefinite quantity...
This is a firm-fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The $1,405,301.00 contract is for in vitro evaluation of the toxic profiles of tobacco additives using a systematic tiered approach. It is part of the larger "In Vivo Toxicology of Tobacco 2015-2020" indefinite delivery, indefinite quantity (IDIQ) contract vehicle....
This firm fixed-price delivery order was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $2,472,244.00 contract is for the evaluation of e-cigarette aerosol in in vivo nonclinical models and was issued under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery, indefinite quantity (IDIQ) contract. Lovelace Biomedical Research Institute has...
This is a firm fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $3,872,713 task order is for a study titled "ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS". The work is not set aside. Lovelace has experience supporting the National Institutes of Health (NIH), Department of...
This is a firm fixed-price delivery order awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The contract has a potential value of $1,835,595.00 and is for a study to investigate the subjective effects and nicotine pharmacokinetics of mentholated smokeless tobacco products in current users. The contract is part of a larger Tobacco Products Pharmacology Study indefinite...
This is a $2,130,022 delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract, titled "CTP-2022-111127 - SALTS", has a completion date of September 22, 2026 and does not have a set-aside designation. Lovelace Biomedical Research Institute has extensive experience supporting federal agencies like the National Institutes of Health (NIH), Department of...